Quantitative LAL (Limulus Amebocyte Lysate) endotoxin testing for injectable peptides, compounding pharmacy batches, and research-grade materials. Compliant with USP <85> and Ph.Eur. 2.6.14.
LAL (Limulus Amebocyte Lysate) testing quantifies bacterial endotoxins (lipopolysaccharides) in pharmaceutical and research-grade peptides. Endotoxins from gram-negative bacteria can cause severe pyrogenic (fever) reactions if injected, making LAL testing essential for any injectable peptide formulation. Cert Biohealth Testing Labs performs quantitative kinetic turbidimetric and chromogenic LAL assays per USP <85> with a detection limit of 0.005 EU/mL.
Quantitative measurement of endotoxin concentration using turbidity change over time. Preferred for compounding pharmacy and pharmaceutical applications requiring precise EU/mg values.
Colorimetric quantification using a chromogenic substrate for highly sensitive endotoxin detection in complex peptide matrices.
Pass/fail endotoxin limit test suitable for screening applications where a specific EU/mg threshold must be confirmed.
Method validation including spike-and-recovery experiments to confirm the absence of interference from the peptide matrix.
| Application | Endotoxin Limit | Reference |
|---|---|---|
| Parenteral drugs (>10 mL/dose) | 0.2 EU/mL | USP <85> / Ph.Eur. 2.6.14 |
| Parenteral drugs (≤10 mL/dose) | 0.5 EU/mL | USP <85> |
| Intrathecal drugs | 0.2 EU/kg/hr | USP <85> |
| Research peptides (in vivo rodent) | 1 EU/kg (recommended) | Industry guidance |
| Cell culture & in vitro | <1 EU/mL (recommended) | Lab standard |
If your peptides will be used in any in vivo animal work, endotoxin testing is strongly recommended. Endotoxins at levels as low as 1 EU/kg can cause fever, inflammation, and confounded study results in rodent models. Many institutional animal care committees (IACUCs) now require endotoxin data before approving in vivo studies.
Both are quantitative methods that meet USP <85> requirements. Kinetic turbidimetric LAL measures the rate of turbidity change caused by endotoxin-activated clotting protein, while chromogenic LAL uses a synthetic chromogenic substrate. We recommend chromogenic LAL for coloured or turbid peptide solutions where turbidity interference is a concern.
Typically 1–5 mg of lyophilized peptide. The exact amount depends on the required dilution factor for your peptide’s matrix interference level. We determine the Maximum Valid Dilution (MVD) based on your peptide’s concentration and the applicable limit.
Yes — some peptides are inhibitory or enhancing toward the LAL reaction, requiring dilution or sample treatment. We routinely perform spike recovery validation on all samples to confirm valid assay conditions. If interference is detected, we adjust the protocol and report all validation data in the final COA.
Yes. Our LAL methods are validated per USP <85> and Ph.Eur. 2.6.14, both of which are recognized by Health Canada’s Drug and Health Products directorate for compounding pharmacy and clinical trial documentation.
USP <85>-compliant LAL endotoxin testing for injectable peptides, compounding batches, and in vivo research materials. Results in 5–7 business days.
+1 (416) 000-0000 | info@certbiohealth.ca